9.2 Biosimilar & Interchangeable Biological Products (Purple Book)

9.2 Biosimilar & Interchangeable Biological Products (Purple Book)

In recent decades, modern therapeutics has shifted substantially from traditional small-molecule chemically synthesized drugs toward biological products—complex, high-molecular-weight proteins, monoclonal antibodies, fusion proteins, cytokines, and cellular therapies produced in living cell lines. Because of their molecular size, structural complexity, and manufacturing sensitivity, biologics cannot be evaluated under traditional generic equivalence models.

To establish an abbreviated pathway for biological product competition, Congress enacted the Biologics Price Competition and Innovation Act of 2009 (BPCIA) as part of the Affordable Care Act, codified in Section 351 of the Public Health Service Act (PHSA; 42 U.S.C. § 262). Concurrently, the State of Oklahoma enacted specialized legislation codified at Title 59 O.S. § 353.21.1 to govern the dispensing, automatic substitution, prescriber notification, and recordkeeping standards for biosimilars and interchangeable biological products.

---

The Three-Tier Biologics Regulatory Hierarchy

Under federal law and FDA regulations, biological products fall into three distinct regulatory tiers:

                   THE THREE-TIER BIOLOGICS REGULATORY PYRAMID

                       /\   [ TIER 3: INTERCHANGEABLE ]
                      /  \  - Meets all biosimilar standards
                     /    \ - Proven to produce same clinical result in any patient
                    /      \- Switching/alternating risk evaluated
                   /--------\- AUTOMATIC SUBSTITUTION PERMITTED IN OKLAHOMA
                  /          \ 
                 /  TIER 2:   \ [ TIER 2: BIOSIMILAR ]
                /  BIOSIMILAR  \- Highly similar to Reference Product
               /                \- No clinically meaningful differences in purity/potency
              /------------------\- CANNOT BE AUTOMATICALLY SUBSTITUTED (Rx Required)
             /                    \
            /       TIER 1:        \ [ TIER 1: REFERENCE PRODUCT ]
           /   REFERENCE PRODUCT    \- Innovator Biologic licensed under PHSA § 351(a)
          /                          \- Original full clinical trial approval
         +----------------------------+

1. Reference Product (Innovator Biologic - PHSA § 351(a))

A Reference Product is the original innovator biological product approved and licensed by the FDA under Section 351(a) of the Public Health Service Act on the basis of a complete Biologics License Application (BLA), which requires extensive pre-clinical data and comprehensive human clinical trials establishing safety, purity, and potency (e.g., Humira [adalimumab], Lantus [insulin glargine], Neupogen [filgrastim], Remicade [infliximab]).

2. Biosimilar Biological Product (PHSA § 351(k))

A Biosimilar is a biological product licensed under the abbreviated 351(k) BLA pathway that is demonstrated to be "highly similar" to the reference product notwithstanding minor differences in clinically inactive components (e.g., minor differences in glycosylation patterns or vehicle excipients), and for which there are no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency.

Critical Legal Rule for MPJE: A product that is approved ONLY as a biosimilar CANNOT be automatically substituted at the pharmacy counter in Oklahoma. Dispensing a biosimilar when the reference product was prescribed requires an explicit, affirmative prescription from the prescriber (or direct prescriber authorization for a product change).

3. Interchangeable Biological Product (PHSA § 351(k) with Interchangeability)

An Interchangeable Biological Product is a biosimilar product that has met additional, rigorous statutory requirements under Section 351(k)(4) of the PHSA:

1. It is biosimilar to the reference product,
2. It can be expected to produce the same clinical result as the reference product in any given patient, and
3. For a biological product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch.

Only products that attain the FDA Interchangeable designation may be substituted for the reference product at the pharmacy counter without the intervention or prior authorization of the prescribing healthcare provider.

---

The FDA Purple Book Database

To identify the regulatory status of biological products, pharmacists reference the FDA Purple Book: Database of Licensed Biological Products.

+-------------------------------------------------------------------------+
|                   FDA PURPLE BOOK vs. FDA ORANGE BOOK                   |
+-------------------------------------------------------------------------+
| Feature           | Orange Book             | Purple Book               |
|-------------------|-------------------------|---------------------------|
| Governing Statute | FDCA § 505              | PHSA § 351                |
| Product Type      | Small-molecule drugs    | Biological products       |
| Equivalence Model | Therapeutic Equivalence | Biosimilar / Interchange- |
|                   | ('A' vs. 'B' codes)     | able Determination        |
| Auto-Substitution | Any 'A' rated generic   | ONLY 'Interchangeable'    |
| Notification Rule | None (standard label)   | 5-Day Prescriber Notice   |
+-------------------------------------------------------------------------+

The Purple Book provides searchable data on all FDA-licensed biological products, including:

• Full proprietary (brand) and non-proprietary (proper) names,
• BLA license number and approval date,
• Exact reference product exclusivity expiration dates,
• Explicit designation whether the product is a Reference Product, a Biosimilar, or an Interchangeable Biosimilar.

---

Oklahoma Interchangeable Biologic Law: Title 59 O.S. § 353.21.1

Oklahoma enacted comprehensive statutory rules governing biological product substitution under Title 59 O.S. § 353.21.1. Pharmacists must adhere to four essential statutory mandates:

1. Conditions for Lawful Substitution

A pharmacist may substitute an interchangeable biological product for a prescribed reference biological product ONLY if:

1. The FDA has determined the product to be interchangeable with the reference product in the Purple Book,
2. The prescribing practitioner has not indicated DAW / Dispense As Written or "Brand Medically Necessary" on the prescription,
3. The patient or purchaser has not requested the reference product, and
4. The pharmacy passes any cost savings on to the purchaser.

2. Mandatory Post-Dispensing Prescriber Communication (The 5-Day Rule)

Within five (5) business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's designee must communicate the specific product provided to the patient to the prescribing practitioner, including the specific name of the product and the manufacturer.

+-------------------------------------------------------------------------+
|              OKLAHOMA 5-DAY BIOLOGIC COMMUNICATION TIMELINE             |
+-------------------------------------------------------------------------+
| Day 0: Interchangeable Biologic Dispensed to Patient                    |
| Day 1 - 5 (Business Days): Communication Transmitted to Prescriber      |
| Method: Interoperable EHR / E-Prescribing / Pharmacy Portal / Fax / Tel |
| Content: Specific Product Name (Proprietary/Proper) + Manufacturer      |
+-------------------------------------------------------------------------+

3. Authorized Communication Mechanisms

Under Title 59 O.S. § 353.21.1, communication to the prescriber is accomplished by making an entry into an interoperable electronic medical records system, an electronic prescribing technology system, a pharmacy benefit management (PBM) system, or a shared pharmacy record portal that is electronically accessible by the prescribing practitioner in the normal course of business. Entering the dispense record into such an electronic system satisfies the statutory communication requirement.

If electronic record-sharing is not available, the pharmacist must communicate the dispensing to the prescriber using facsimile (fax), telephone, electronic transmission, or other prevailing means within the 5 business day window.

4. Statutory Exemptions from Prescriber Communication

Prescriber communication is NOT required under Oklahoma law when:

• There is no FDA-approved interchangeable biological product for the prescribed product (i.e., the brand was dispensed as written), or
• A refill prescription is dispensed where the product dispensed is identical to the biological product dispensed on the prior filling.

5. Recordkeeping Mandate (5-Year Retention)

The pharmacy must maintain a complete record of any biological product dispensed (including specific manufacturer, lot, and substitution details) for a minimum of five (5) years from the date of dispensing, in alignment with Oklahoma Board of Pharmacy record retention requirements.